Hegde et al. measured serum VEGF-A levels by ELISA at baseline, in a large cohort of cancer patients (colorectal cancer, renal cancer and lung cancer) from four randomized phase III studies with experimental bevacizumab-containing regimens [113,114]. This evidence concerns the gene VEGFA and cancer.